3
Announcements
Trials
Browse
Landscape
Status
No longer available
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
981
Observational
309
Expanded_access
3
Sponsor
Cancer Type
Thoracic
3
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
14
Neoplasms
11
Multiple Myeloma
10
Recurrence
9
Pancreatic Neoplasms
8
Prostatic Neoplasms
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Ovarian Neoplasms
6
Neuroblastoma
6
Melanoma
6
Leukemia, Myeloid, Acute
6
Sarcoma
5
Hematologic Neoplasms
4
Glioblastoma
4
Breast Neoplasms
4
Stomach Neoplasms
3
Osteosarcoma
3
Non-Muscle Invasive Bladder Neoplasms
3
Neuroectodermal Tumors, Primitive
3
Myelodysplastic Syndromes
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Squamous Cell
3
Uterine Neoplasms
2
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Interventions
taletrectinib
1
capmatinib
1
Suspensions
1
Powders
1
Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Expanded_access
×
Lung Neoplasms
×
1 year
×
Clear all
NCT04741789
2026-03-16
Managed Access Programs for INC280, Capmatinib
Novartis
No longer available
NCT03756311
2026-01-23
Expanded Access to NanoPac
NanOlogy, LLC
No longer available
NCT06841874
2025-12-24
Tale EAP
Nuvation Bio Inc.
No longer available